FOA was recently published on Stigma, “Reducing Stigma to Improve HIV/AIDS Prevention, Treatment and Care in Low- and Middle-Income Countries (R21 Clinical Trial Optional)” https://grants.nih.gov/grants/guide/pa-files/PAR-19-326.html

... Read more about NEW FOA from FIC; NIDA; NIMH; NCI: "Reducing Stigma to Improve HIV/AIDS Prevention, Treatment and Care in Low- and Middle-Income Countries" (R21 Clinical Trial Optional)

At NIH, we are heavily invested in our workforce and in understanding the barriers they face. What characteristics do they share? How do they compete in the current hypercompetitive environment? When do they stop applying to NIH (drop out), even after receiving their first award? Staff from the National Institute of Allergy and Infectious Diseases (NIAID) delve into these questions in a paper published recently in PLOS ONE , whose findings I’d like to highlight today. Here, Drs. Patricia Haggerty and Matthew Fenton looked at factors that may contribute to the success of early-career... Read more about What Contributes to the Success of Early Career Scientists? – A NIAID Look

Announcement (FOA) Number PAR-17-471 

The purpose of this Funding Opportunity Announcement is to support bi-phasic developmental, discovery-driven, or hypothesis-driven research focused on innovative strategies to detect HIV either within the first two weeks of infection or to monitor viral rebound after stopping or developing resistance to antiretroviral therapy. Applications should propose simple dignostic tools that would be feasible for a self-testing platform to allow untrainded individuals to detect HIV. Interdisciplinary collaborations that include...

Read more about Funding Opportunity: Detection of HIV for Self-Testing (R61/R33)

HIV infection increases mortality in African women with cervical cancer

“Botswana was the first country in Africa to provide comprehensive HIV treatment to its citizens and has one of the most effective antiretroviral treatment programs globally,” Scott Dryden-Peterson, MD, instructor of medicine at Harvard Medical School and associate physician at Brigham and Women’s Hospital, told HemOnc Today. “As such, trends in Botswana are indicative of what will happen in other heavily HIV affected countries that also now have good access...

Read more about Botswana’s cautionary tale of the co-epidemic of HIV and cervical cancer